Effects of chloroquine on viral infections: an old drug against today's diseases?

Andrea Savarino, Johan R Boelaert, Antonio Cassone, Giancarlo Majori, Roberto Cauda, Andrea Savarino, Johan R Boelaert, Antonio Cassone, Giancarlo Majori, Roberto Cauda

Abstract

Chloroquine is a 9-aminoquinoline known since 1934. Apart from its well-known antimalarial effects, the drug has interesting biochemical properties that might be applied against some viral infections. Chloroquine exerts direct antiviral effects, inhibiting pH-dependent steps of the replication of several viruses including members of the flaviviruses, retroviruses, and coronaviruses. Its best-studied effects are those against HIV replication, which are being tested in clinical trials. Moreover, chloroquine has immunomodulatory effects, suppressing the production/release of tumour necrosis factor alpha and interleukin 6, which mediate the inflammatory complications of several viral diseases. We review the available information on the effects of chloroquine on viral infections, raising the question of whether this old drug may experience a revival in the clinical management of viral diseases such as AIDS and severe acute respiratory syndrome, which afflict mankind in the era of globalisation.

Figures

Figure 1
Figure 1
Steps of the replication of different viruses affected by chloroquine (marked by red rectangles). Chloroquine inhibits the replication of different viruses either at the early or late stages of viral replication.
Figure 2
Figure 2
Effects of chloroquine on the immune system. TNFα is produced by activated monocytes/macrophages. Among its multiple functions it helps to activate resting monocytes and favours extravasation of neutrophils by opening tight junctions between human vascular endothelial cells and upregulating leucoyte adhesion molecules (LAM). Chloroquine diminishes TNFα production and downregulates the TNFα receptors 1 and 2 (TNFR) on the monocyte cell surface, which eventually results in decreasedmonocyte activation as well as decreased leucocyte extravasation. Red crosses mark the steps directly inhibited by chloroquine.
Figure 3
Figure 3
Hypothetical model for the potential effects of chloroquine (CQ) on the immunopathogenesis of severe acute respiratory syndrome (SARS). Proinflammatory cytokines are thought to be important in acute respiratory distress syndrome (ARDS). We hypothesise that chloroquine (black arrow), by inhibiting TNFα and interleukin 6 (IL6) production, might block the subsequent cascade of events, which leads to ARDS.

References

    1. Canadian rheumatology association Canadian Consensus Conference on hydroxychloroquine. J Rheumatol. 2000;27:2919–2921.
    1. Savarino A, Gennero L, Sperber K, Boelaert JR. The anti-HIV-1 activity of chloroquine. J Clin Virol. 2001;20:131–135.
    1. Boelaert JR, Piette J, Sperber K. The potential place of chloroquine in the treatment of HIV-1–infected patients. J Clin Virol. 2001;20:137–140.
    1. Ohkuma S, Poole B. Cytoplasmic vacuolation of mouse peritoneal macrophages and the uptake into lysosomes of weakly basic substances. J Cell Biol. 1981;90:656–664.
    1. Pescarmona GP, Morra E, Aldieri E, Ghigo D, Bosia A. Movements of vesicles in eukaryotic cells: role of intravesicle protons as a fuel and modulation of their concentration by drugs or metabolic changes. MRS Bull. 1998;489:212–217.
    1. Vezmar M, Georges E. Reversal of MRP-mediated doxorubicin resistance with quinoline-based drugs. Biochem Pharmacol. 2000;59:1245–1252.
    1. Vezmar M, Georges E. Direct binding of chloroquine to the multidrug resistance protein (MRP): possible role for MRP in chloroquine drug transport and resistance in tumor cells. Biochem Pharmacol. 1998;56:733–742.
    1. Byrd TF, Horwitz MA. Chloroquine inhibits the intracellular multiplication of Legionella pneumophila by limiting the availability of iron. A potential new mechanism for the therapeutic effect of chloroquine against intracellular pathogens. J Clin Invest. 1991;88:351–357.
    1. Legssyer R, Josse C, Piette J, Ward RJ, Crichton RR. Changes in function of iron-loaded alveolar macrophages after in vivo administration of desferrioxamine and/or chloroquine. J Inorg Biochem. 2003;94:36–42.
    1. Gonzalez-Dunia D, Cubitt B, de la Torre JC. Mechanism of Borna disease virus entry into cells. J Virol. 1998;72:783–788.
    1. Ros C, Burckhardt CJ, Kempf C. Cytoplasmic trafficking of minute virus of mice: low-pH requirement, routing to late endosomes, and proteasome interaction. J Virol. 2002;76:12634–12645.
    1. Diaz-Griffero F, Hoschander SA, Brojatsch J. Endocytosis is a critical step in entry of subgroup B avian leukosis viruses. J Virol. 2000;76:12866–12876.
    1. Bishop NE. Examination of potential inhibitors of hepatitis A virus uncoating. Intervirology. 1998;41:261–271.
    1. Ferreira DF, Santo MP, Rebello MA, Rebello MC. Weak bases affect late stages of Mayaro virus replication cycle in vertebrate cells. J Med Microbiol. 2000;49:313–318.
    1. Harley CA, Dasgupta A, Wilson DW. Characterization of herpes simplex virus-containing organelles by subcellular fractionation: role for organelle acidification in assembly of infectious particles. J Virol. 2001;75:1236–1251.
    1. Randolph VB, Winkler G, Stollar V. Acidotropic amines inhibit proteolytic processing of flavivirus prM protein. Virology. 1990;174:450–458.
    1. Tsai WP, Nara PL, Kung HF, Oroszlan S. Inhibition of human immunodeficiency virus infectivity by chloroquine. AIDS Res Hum Retroviruses. 1990;6:481–489.
    1. Baughman RP, Lower EE, du Bois RM. Sarcoidosis. Lancet. 2003;361:1111–1118.
    1. Jeong J-Y, Jue D-M. Chloroquine inhibits processing of tumor necrosis factor in lipopolysaccharidestimulated RAW 264·7 macrophages. J Immunol. 1997;158:4901–4907.
    1. Bondeson J, Sundler R. Antimalarial drugs inhibit phospholipase A2 activation and induction of interleukinβ and tumor necrosis factor α in macrophages. General Pharmacol. 1998;30:357–366.
    1. Van den Borne BE, Dijkmans BA, de Rooij HH, le Cessie S, Verweij CL. Chloroquine and hydroxychloroquine equally affect tumor necrosis factor-α, interleukin 6 and interferon-γ production by peripheral blood mononuclear cells. J Rheumatol. 1997;24:55–60.
    1. Karres I, Kremer J-P, Dietl I, Steckholzer U, Jochum M, Ertel W. Chloroquine inhibits proinflammatory cytokine release into human whole blood. Am J Physiol. 1998;274:R1058–R1064.
    1. Picot S, Peyron F, Donadille A, Vuillez J-P, Barbe G, Ambroise-Thomas P. Chloroquine-induced inhibition of the production of TNF, but not of IL-6, is affected by disruption of iron metabolism. Immunology. 1993;80:127–133.
    1. Weber SM, Levitz SM. Chloroquine interferes with lipopolysaccharide-induced TNF-α gene expression by a nonlysosomotropic mechanism. J Immunol. 2000;165:1534–1540.
    1. Jeong J-Y, Choi JW, Jeon K-I, Jue D-M. Chloroquine decreases cell-surface expression of tumour necrosis factor receptors in human histiocytic U-937 cells. Immunol. 2002;105:83–91.
    1. Nooteboom A, Hendriks T, Otteholler I, van der Linden CJ. Permeability characteristics of human endothelial monolayers seeded on different extracellular matrix proteins. Mediators Inflamm. 2000;9:235–241.
    1. Bernstein HN. Ocular safety of hydroxychloroquine. Ann Ophthalmol. 1991;23:292–296.
    1. Bernstein HN. Ophthalmologic considerations and testing in patients receiving long-term antimalarial therapy. Am J Med. 1983;75:25–34.
    1. Herman K, Leys A, Spileers W. (Hydroxy)-chloroquine retinal toxicity: two case reports and safety guidelines. Bull Soc Belge Ophtalmol. 2002;284:21–29.
    1. Klinger G, Morad Y, Westall CA. Ocular toxicity and antenatal exposure to chloroquine or hydroxychloroquine for rheumatic diseases. Lancet. 2001;358:813–814.
    1. Sperber K, Kalb TH, Stecher VJ, Banerjee R, Mayer L. Inhibition of human immunodeficiency virus type 1 replication by hydroxychloroquine in T cells and monocytes. AIDS Res Hum Retroviruses. 1993;9:91–98.
    1. Pardridge WM, Yang J, Diagne A. Chloroquine inhibits HIV-1 replication in human peripheral blood lymphocytes. Immunol Lett. 1998;64:45–47.
    1. Savarino A, Gennero L, Chen HC. Anti-HIV effects of chloroquine: mechanisms of inhibition and spectrum of activity. AIDS. 2001;15:2221–2229.
    1. Sperber K, Louie M, Kraus T. Hydroxychloroquine treatment of patients with human immunodeficiency virus type 1. Clin Ther. 1995;17:622–636.
    1. Sperber K, Chiang G, Chen H. Comparison of hydroxychloroquine with zidovudine in asymptomatic patients infected with HIV-1. Clin Ther. 1997;19:913–923.
    1. Debiaggi M, Bruno R, Sacchi P, Filice G. Antiviral activity of chloroquine against HIV-1 strains resistant to antiretroviral drugs. Antiviral Res (in press)
    1. Chiang G, Sassaroli M, Louie M, Chen H, Stecher VJ, Sperber K. Inhibition of HIV-1 replication by hydroxychloroquine: mechanism of action and comparison with zidovudine. Clin Ther. 1996;18:1080–1092.
    1. Boelaert JR and Sperber K. Antiretroviral therapy. Lancet. 1998;352:1224–1225.
    1. Boelaert JR, Sperber K, Piette J. Chloroquine exerts an additive in vitro anti-HIV-1 effect, when combined to zidovudine and hydroxyurea. Biochem Pharmacol. 2001;61:1531–1535.
    1. Paton NI, Aboulhab J, Karim F. Hydroxychloroquine, hydroxycarbamide, and didanosine as economic treatment for HIV-1. Lancet. 2002;359:1667–1668.
    1. Boelaert JR, Dom GM, Huitema AD, Beijnen JH, Lange JM. The boosting of didanosine by allopurinol permits a halving of the didanosine dosage. AIDS. 2002;16:2221–2223.
    1. Mofenson LM, McIntyre JA. Advances and research directions in the prevention of mother-to-child HIV-1 transmission. Lancet. 2000;355:2237–2244.
    1. Boelaert JR, Yaro S, Augustijns P. Chloroquine accumulates in breast milk cells. Potential impact as adjuvant to antiretroviral prophylaxis for postnatal mother-to-child transmission of HIV-1. AIDS. 2001;15:2205–2206.
    1. DeCock KM, Fowler MG, Mercier E. Prevention of mother-to-child transmission of HIV-1 in resource-poor countries: translating research into policy and practice. JAMA. 2000;283:1175–1182.
    1. Corbett EL, Steketee RW, ter Kuile FO, Latif AS, Kamali A, Hayes RJ. HIV-1/AIDS and the control of other infectious diseases in Africa. Lancet. 2002;359:2177–2187.
    1. Clerici M, Butto S, Lukwiya M. Immune activation in Africa is environmentally driven and is associated with upregulation of CCR5. AIDS. 2000;14:2083–2092.
    1. Bentwich Z, Maartens G, Torten D, Lal AA, Lal RB. Concurrent infections and HIV pathogenesis. AIDS. 2000;14:2071–2081.
    1. Montano MA, Nixon CP, Ndung'u T. Elevated tumor necrosis factor-α activation of human immunodeficiency virus subtype 1 in southern Africa is associated with an NF-kB enhancer gain-of-function. J Infect Dis. 2000;181:76–81.
    1. Poutanen SM, Low DE, Henry B. Identification of severe acute respiratory syndrome in Canada. N Engl J Med. 2003;348:1995–2005.
    1. So LK, Lau AC, Yam LY. Development of a standard treatment protocol for severe acute respiratory syndrome. Lancet. 2003;361:1615–1617.
    1. Peiris JS, Lai ST, Poon LL. Coronavirus as a possible cause of severe acute respiratory syndrome. Lancet. 2003;361:1319–1325.
    1. Drosten C, Gunther S, Preiser W. Identification of a novel coronavirus in patients with severe acute respiratory syndrome. N Engl J Med. 2003;348:1967–1976.
    1. Blau D, Holmes K. Human Coronavirus HCoV-229E enters susceptible cells via the endocytic pathway. In: Lavi E, editor. The Nidoviruses, Coronaviruses and Arteriviruses. Kluwer; New York: 2001. pp. 193–197.
    1. Nauwynck HJ, Duan X, Favoreel HW, Van Oostveldt P, Pensaert MB. Entry of porcine reproductive and respiratory syndrome virus into porcine alveolar macrophages via receptor-mediated endocytosis. J Gen Virol. 1999;80(Pt 2):297–305.
    1. Peiris JS, Chu CM, Cheng VC. Clinical progression and viral load in a community outbreak of coronavirus-associated SARS pneumonia: a prospective study. Lancet. 2003;361:1767–1772.
    1. Shanley TP, Warner RL, Ward PA. The role of cytokines and adhesion molecules in the development of inflammatory injury. Mol Med Today. 1995;1:40–45.
    1. Nicholls JM, Poon LL, Lee KC. Lung pathology of fatal severe acute respiratory syndrome. Lancet. 2003;361:1773–1778.
    1. Van Reeth K, Van Gucht S, Pensaert M. In vivo studies on cytokine involvement during acute viral respiratory disease of swine: troublesome but rewarding. Vet Immunol Immunopathol. 2002;87:161–168.
    1. Fenollar F, Fournier PE, Carrieri MP, Habib G, Messana T, Raoult D. Risks factors and prevention of Q fever endocarditis. Clin Infect Dis. 2001;33:312–316.
    1. Ladner J, Leroy V, Karita E, van de Perre P, Dabis F. Malaria, HIV and pregnancy. AIDS. 2003;17:275–356.
    1. Savarino A, Bottarel F, Malavasi F, Dianzani U. Role of CD38 in HIV-1 infection: an epiphenomenon of T-cell activation or an active player in virus/host interactions? AIDS. 2000;14:1079–1089.

Source: PubMed

Szponzorok és közreműködők

Egészségi állapot

Kábítószer-beavatkozások

3
Iratkozz fel